HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    
Learn more
Self Investors Wanted Today

Few spots available. Master Zacks' market-tripling Stock Picking Method in your home at our cost.
Opportunity ends Saturday, Nov. 21 >>

Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

ALXN: Alexion Pharmaceuticals Inc - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

ALEXION PHARMACEUTICALS INC (NASD)
ALXN 43.70 -0.46 (-1.04%) Vol.  429,350 16:00 ET

Day Low - High 43.63 - 44.27
52wk Low - High N/A - 48.93
Avg Volume 808,141
Industry MED-BIOMED/GENE
Market Cap 3.84 B
Div - Yield 0.00 - 0.00
PE (forward) 49.89
PEG Ratio 1.3
Current Year Est. .88
EPS Last Year 0.85
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 09/03/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
ALEXION PHARMACEUTICALS INC ALXN PREMIUM
DISCOVERY LABS DSCO PREMIUM
MOMENTA PHARMA MNTA PREMIUM
LPATH INC LPTN PREMIUM
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.63
ABR (Last Week) 1.63
# of Recs in ABR 19
Average Target Price 50.40
Industry Rank by ABR 48 out of 217
Rank in Industry 80 out of 171
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate ALXN?
Buy
Sell
Find out what the Zacks Community
thinks of ALXN at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR ALXN
Zacks Blog: Alexion Beats, Raises Outlook
Oct 23, 2009
Zacks Equity Research: Report for ALXN
Sep 03, 2009
Zacks Blog: Alexion earnings beat estimates
Jul 24, 2009
Zacks Blog: Alexion Targets Soliris Expansion
Jul 02, 2009
Zacks Blog: Alexion - Still a 1-Drug Wonder
Apr 27, 2009
More Zacks Commentary
NEWS
Alexion Pharmaceuticals to Present Soliris Data at Annual ASH Meeting
Nov 13, 2009
BiomedReports: News and FDA Updates for NexMed (Nasdaq:NEXM), ORC (NASDAQ:IUSA), Alexion (Nasdaq:ALXN)
Nov 12, 2009
BiomedReports: News and FDA Updates for Alexion (Nasdaq:ALXN), Biogen (NASDAQ:BIIB), Elan (NYSE:ELN)
Nov 11, 2009
Alexion to Present at Lazard Capital Markets 6th Annual Healthcare Conference
Nov 11, 2009
Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of Patients With PNH at the ASH Annual Meeting
Nov 10, 2009
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate 0.24 0.26 0.88 1.26
Number of Estimates 16 7 15 15
Low Estimates 0.18 0.17 0.75 0.98
High Estimate 0.29 0.35 0.93 1.76
Year Ago EPS 0.17 0.16 0.39 0.88
EPS Growth 38.60% 64.29% 124.62% 43.68%

More Estimates

COMPANY DESCRIPTION
Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.

Full Company Report
FINANCIALS
EPS TTM .85
Sales 259.1
Net Income 73.38
Price/Earnings 51.41
Price/Book 9
Price/Cash Flow 83.57
Price/Sales 10.87


More Financials

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research